Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
Robert A Hauser,1 Aaron Ellenbogen,2 Sarita Khanna,3 Suneel Gupta,3 Nishit B Modi3 1Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, FL, USA; 2Quest Research Institute, Bingham Farms, MI, USA; 3Impax Laboratories, Inc., Hayward, CA, USA Backgrou...
Guardado en:
Autores principales: | Hauser RA, Ellenbogen A, Khanna S, Gupta S, Modi NB |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/688a03100d9d4bfab5fa1ae90a6dd60d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparación farmacocinética de Sinemetây Grifoparkinâ (levodopa/carbidopa 250/25 mg) en pacientes con enfermedad de Parkinson avanzada: un estudio con dosis única
por: Chaná C,Pedro, et al.
Publicado: (2003) -
Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman DY, et al.
Publicado: (2018) -
Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
por: Constantin VA, et al.
Publicado: (2020) -
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010) -
Protein intake and the use of levodopa in patients with Parkinson's disease
por: de Moraes Fracasso,Bianca, et al.
Publicado: (2013)